Header

Breast: Metastatic Clinical Trials

Category:Adult
Status:Active

Displaying trials 1 - 30 of 46 in total

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative bre...

Diagnosis: Breast: Metastatic

Phase: 3

Protocol Number: 15-716

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that is thought to work by in...

Diagnosis: Brain/Neuro Cancer: Other Non-Glioblastoma, Breast: Metastatic

Phase: 2

Protocol Number: 06-268

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Diagnosis: Breast: Metastatic

Phase: 2

Protocol Number: 13-237

Cisplatin vs Paclitaxel for Triple Neg

This research study is evaluating how well triple negative breast cancer responds to preoperative treatment with Cisplatin or Paclitaxel chemotherapy, and if use of a research test Homologous Recom...

Diagnosis: Breast: Metastatic, Breast: Early Stage Disease

Phase: 2

Protocol Number: 13-383

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

This research study is evaluating the effectiveness of the drug called cabozantinib (alone or in combination with trastuzumab) as a possible treatment for advanced breast cancer in which the cancer...

Diagnosis: Breast: Metastatic

Phase: 2

Protocol Number: 14-359

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung c...

Diagnosis: Breast: Metastatic

Phase: 2

Protocol Number: 15-058

Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer

The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced ER+ and AR+ breast c...

Diagnosis: Breast: Metastatic

Phase: 2

Protocol Number: 15-451

Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

This research study is testing the safety and feasibility of delivering the 4 cycles of 'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte Colony-stimulati...

Diagnosis: Breast: Metastatic, Breast: Early Stage Disease

Phase: 2

Protocol Number: 15-516

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant or chemotherapy in women with hormone receptor positive (HR+), human epidermal...

Diagnosis: Breast: Metastatic

Phase: 2

Protocol Number: 16-014

A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

Approximately 70 patients with HR+ advanced breast cancer will be enrolled. All patients will receive either fulvestrant (500 mg IM every 2 weeks x 3 then every four weeks) or tamoxifen (20 mg PO d...

Diagnosis: Breast: Metastatic

Phase: 2

Protocol Number: 16-035

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone re...

Diagnosis: Lung Cancer, Breast: Metastatic

Phase: 2

Protocol Number: 16-216

Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

The purpose of this study is to assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent cent...

Diagnosis: Breast: Metastatic

Phase: 2

Protocol Number: 16-092

A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer

The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of VT-464, a lyase-selective inhibitor of CYP17, in patients with advanced breast cancer.

Diagnosis: Breast: Metastatic

Phase: 1 / 2

Protocol Number:

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Participants that have breast cancer that has spread to other parts of the body, is positive for a protein called HER2, and has not responded to standard treatment. This research study is a way of ...

Diagnosis: Breast: Metastatic

Phase: 1 / 2

Protocol Number: 15-530

Palbociclib With Everolimus + Exemestane In BC

This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor ...

Diagnosis: Breast: Metastatic

Phase: 1 / 2

Protocol Number: 16-177

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

The purpose of this trial is to inform the future clinical development of the two investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha inhibitor). This is a...

Diagnosis: Breast: Metastatic

Phase: 1

Protocol Number: 13-367

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

The main purpose of this study is to evaluate the safety of a study drug known as LY2835219 in combination with different therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus e...

Diagnosis: Breast: Metastatic

Phase: 1

Protocol Number: 14-070

A Safety Study of SGN-LIV1A in Breast Cancer Patients

This study will examine the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer. Increasing doses of SGN-LIV1A will be given every 3 weeks alone or in combination with tr...

Diagnosis: Breast: Metastatic

Phase: 1

Protocol Number: 14-306

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single a...

Diagnosis: Breast: Metastatic

Phase: 1

Protocol Number:

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have a dose escalation to identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus pa...

Diagnosis: Breast: Metastatic

Phase: 1

Protocol Number:

Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

This phase I trial studies the side effects and best dose of olaparib and Hsp90 inhibitor AT13387 when given together in treating patients with solid tumors that have spread to other places in the ...

Diagnosis: Breast: Metastatic, GYN: Ovarian, Fallopian, Peritoneal Cancer

Phase: 1

Protocol Number: 17-715

Novel Social Media Intervention For Older Br CA Patients

The number of patients 60 and older with breast cancer is increasing as our population ages. Despite the fact that the majority of breast cancers occur in patients 60 and over, these patients are c...

Diagnosis: Breast: Metastatic

Phase: N/A

Protocol Number: 15-326

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated ...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 14-316

Study of SRN-927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

This is an open-label, dose-finding study of SRN-927 administered orally on a continuous daily dosing regimen with a PK lead-in period (dose escalation period only). The incidence of dose limiting ...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 14-569

A Phase I, Multicenter, Open-Label, Two-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of RAD1901 in patients with advanced ER+, HER2-negative breast cancer.

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 15-417

Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer

This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer ...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Breast: Metastatic

Phase:

Protocol Number: 15-550

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

The purpose of this Phase II study is to evaluate the efficacy and safety of Continuous Low- Irradiance Photodynamic Therapy (CLIPT) when used with Verteporfin in the treatment of cutaneous metasta...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 16-370

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

The purpose of this study is determine if the triplet combination of ribociclib, everolimus and exemastane is effective in the treatment of locally advanced/metastatic breast cancer following treat...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 16-320

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

This Phase 1b trial is an open label, multi-center study of XMT-1522 administered as an intravenous infusion once every three weeks. The dose escalation part of the study will establish the maximum...

Diagnosis: Breast: Metastatic, Solid Tumor/Phase I

Phase:

Protocol Number: 16-472

CISPLATIN + AZD-1775 In Breast Cancer

This research study is studying a combination of drugs as a possible treatment for triple-negative breast cancer that has spread to other areas of the body. The names of the study interventions inv...

Diagnosis: Breast: Metastatic

Phase:

Protocol Number: 16-264

1
<< Previous
'